XHKG
9933
Market cap198mUSD
Oct 05, Last price
1.65HKD
1D
0.61%
1Q
5.10%
IPO
392.54%
Name
GHW International
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GHW International is an investment holding company that manufactures and globally distributes a variety of chemical and pharmaceutical products. Its operations reach across the People's Republic of China, Europe, Vietnam, other Asian regions, and various international markets. The company organizes its business into four primary divisions: Polyurethane Materials, Animal Nutrition Chemicals, Fine Chemicals, and Pharmaceutical Products and Intermediates. The Polyurethane Materials division supplies polymeric methylene diphenyl diisocyanate (PMDI), toluene diisocyanate (TDI), and polymer polyether, which are integral to the production of cushion foams, vehicle interior components, and other lightweight automotive parts. Its Animal Nutrition Chemicals segment provides choline chloride and betaine, essential compounds used in feed formulations for poultry and livestock. The Fine Chemicals division produces various substances, including carboxylic acids, solvents, resins, and oleochemicals. These find applications in paints, dye synthesis, lubricant manufacturing, emulsifiers, cosmetics, flavors, fragrances, and feed additives. Lastly, the Pharmaceutical Products and Intermediates segment manufactures and markets compounds like isooctanoic acid and diethyl sulfate. These are utilized as paint driers, fungicides, preservatives, and pharmaceutical raw materials, as well as in the synthesis of dyes, pesticides, and pharmaceutical intermediates. This segment also offers iodine and its derivatives, along with finished pharmaceutical products, such as cefpodoxime dispersible tablets. GHW International was established in 1995 and its main offices are situated in Nanjing, People's Republic of China.
Key people
Yanbin Yin
Executive Chairman of the Board, Chief Executive Officer, Founder · since 2018
Wing Hou Wu
Chief Financial Officer, Company Secretary
Hua Chen
Executive Director · since 2018
Zhaohui Chen
Executive Director · since 2018
Cheng Diao
Executive Director · since 2021
Chunnian Zhou
Executive Director · since 2018
Zhaohui Zhuang
Executive Director · since 2018
Hong Jiang
Deputy Chief Financial Officer
Hongbin Sun
Non-Executive Independent Director · since 2019
Guangji Wang
Non-Executive Independent Director · since 2019
Qing Zheng
Non-Executive Independent Director · since 2019
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||